On a preliminary basis, Exact Sciences (NASDAQ:EXAS) expects Q4 and full-year revenue of $294M – 296M and $874.5M – 876.5M, respectively. Screening revenue should be $229M – 230M (+61%) and $809.5M – 810.5M (+78%), respectively.
Cologuard test volume: 477K (+63%) and 1.68M (+80%), respectively.
Oncotype DX test volume: 41K (+14%) and 156K (+14%), respectively.
Management will provide 2020 guidance during its Q4 earnings call next month.
#JPM20
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.